MicroRNA Biomarkers and Platelet Reactivity: The Clot Thickens by Sunderland, N et al.
CIRCRES/2016/309303/R1 
 
 1
 
 
MicroRNA Biomarkers and Platelet Reactivity –  
the “Clot” Thickens 
 
 
Nicholas Sunderland1, Philipp Skroblin1, Temo Barwari1, Rachael P. Huntley2,  
Ruifang Lu1, Abhishek Joshi1, Ruth C. Lovering2, Manuel Mayr1 
 
 
1 King's British Heart Foundation Centre, King's College London, United Kingdom 
2 Centre for Cardiovascular Genetics, Institute of Cardiovascular Science, University College 
London, London, United Kingdom 
 
 
 
 
 
 
 
Short Title: Non-coding RNAs in platelets 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corresponding author:  
Prof. Manuel Mayr, King’s British Heart Foundation Centre, King’s College London, 125 
Coldharbour Ln, London SE5 9NU, United Kingdom, Fax number: +44 (0)20 7848 5132, Tel 
number: +44 (0)20 7848 5132; email: manuel.mayr@kcl.ac.uk   
CIRCRES/2016/309303/R1 
 
 2
Abstract 
  
Over the last few years, several groups have evaluated the potential of microRNAs 
(miRNAs) as biomarkers for cardiometabolic disease. In this review we discuss the 
emerging literature on the role of miRNAs and other small non-coding RNAs in platelets and 
the circulation, and the potential use of miRNAs as biomarkers for platelet activation. 
Platelets are a major source of miRNAs, YRNAs and circular RNAs. By harnessing multi–
omics approaches, we may gain valuable insights into their potential function. Since not all 
miRNAs are detectable in the circulation, we also created a Gene Ontology (GO) annotation 
for circulating miRNAs using the GO term "extracellular space” as part of blood plasma. 
Finally, we share key insights for measuring circulating miRNAs. We propose ways to 
standardize miRNA measurements, in particular by using platelet-poor plasma to avoid 
confounding caused by residual platelets in plasma, or by adding RNase inhibitors to serum 
to reduce degradation during sample storage. This should enhance comparability of miRNA 
measurements across different cohorts. We provide recommendations for future miRNA 
biomarker studies, emphasizing the need for accurate interpretation within a biological and 
methodological context. 
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Non-Standard Abbreviations and Acronyms 
 
circRNAs  - circular RNAs 
Ct  - cycle threshold  
GO  - gene ontology  
lncRNAs -  long non-coding RNAs  
miRNA  -  microRNA 
MP  - microparticles 
NGS   - next generation sequencing 
PPP  -  platelet-poor plasma  
PRP   - platelet-rich plasma 
qPCR  - quantitative polymerase chain reaction 
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Introduction 
 
Platelets play a key role in hemostasis, initiating and propagating thrombosis.1 Dysregulation 
and inappropriate activation of platelets underpins a wide range of important diseases, 
including stroke and myocardial infarction, whereas impairment of platelet function results in 
bleeding disorders. Platelets are anucleate, and were previously considered to be simple 
cytoplasmic fragments of megakaryocytes. We now know that platelets house an array of 
molecules including proteins, RNA and the subcellular machinery of de novo protein 
synthesis. Platelets can synthesize new proteins, such as the integrin alpha3 (glycoprotein-
IIIa) protein and the fibrinogen receptor.2,3 Platelets contain messenger RNA (mRNA) which 
codes for around a third of human genes.4,5 More recently, the discoveries that platelets are 
an abundant source of microRNAs (miRNA)6, and that miRNA expression profiles within 
platelets correlate with platelet reactivity7, raised the exciting possibility of novel therapeutic 
targets and disease biomarkers. 
 
Initial studies by Mitchell et al revealed that not all miRNAs in the circulation are 
intracellular.8 This pool of extra-cellular ‘circulating miRNA’ consists of miRNA within 
microvesicles, exosomes, or bound to proteins. The finding that miRNAs can also be 
measured in cell-free serum and plasma was surprising, given their high RNase activity. 
Compared to mRNAs, miRNAs remain relatively stable in the circulation through several 
protective mechanisms; association with binding proteins, lipoproteins, or housing in shed 
microvesicles such as exosomes or microparticles (MPs).9-12 Platelets release MPs, 
particularly during activation. These vesicles contain a host of proteins, inflammatory 
mediators, and non-coding RNAs.13-15 Microvesicles might be taken up by other cells, 
introducing another layer of complexity in terms of intercellular signaling by potentially 
allowing direct regulation of the recipient cell’s mRNA profile and gene expression.16,17 Given 
this emerging role for circulating miRNAs, plasma and serum miRNA profiles may find use in 
clinical practice as novel markers of disease, organ function and prognosis.18 
 
In this review we bring together nearly a decade’s experience with circulating non-
coding RNAs, with particular focus on platelet-derived and associated miRNAs, YRNAs, long 
non-coding RNAs, and circular RNAs. We conducted a literature search in PubMed as 
queried on the 23rd November 2016 using the search terms “platelet* AND (miRNA[MeSH 
Terms] OR micro RNA[MeSH Terms] OR micro-RNA OR microRNA)”. 434 results were 
retrieved, of which 75 were relevant primary research papers, and 39 were relevant literature 
reviews. From the literature to date, we collate the known platelet repertoire of non-coding 
RNAs and contemplate their physiological significance. We also examine their disease 
associations and potential clinical applications. Finally, we discuss the practical challenges 
in measuring and comparing miRNA levels, highlighting obstacles that will need to be 
overcome for this relatively new field to come of age. 
 
Non-coding RNAs in platelets and the circulation 
 
Different non-coding RNAs have been described (Figure 1): 
 
miRNAs. The human genome codes for small (~22 nucleotide) regulatory RNA 
molecules, termed miRNAs or miRs. Since miRNAs were first discovered in 1993, over 2500 
have been defined, comprising 1–5% of mammalian genes.19,20 They are highly 
evolutionarily conserved and important in the posttranscriptional regulation of protein 
expression – about one third to half of the human genes is estimated to be regulated by 
miRNAs.21-23 MiRNAs act by imperfect Watson-Crick base pairing to the 3’-UTR of target 
mRNA to affect translation or induce degradation.24,25 MiRNAs can be expressed as 
standalone scripts or alongside the parent gene mRNA. In either case, the primary miRNA 
transcript is processed by the nuclear microprocessor complex consisting of the 
endoribonuclease Drosha and the double-stranded RNA-binding protein Pasha/DGCR8.26,27 
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The resultant “hairpin” pre-miRNA is then transferred to the cytoplasm by the nuclear 
membrane protein exportin-5 and further processed by the endoribonuclease Dicer.28 The 
resulting mature miRNA duplex associates with an Argonaute (Ago) protein which unwinds 
the double strand and incorporates one of the two complementary miRNA strands, forming 
the RNA-induced silencing complex.29 The RNA-induced silencing complex stabilizes the 
miRNA strand and guides it to its target mRNA. Since platelets do not have a nucleus and 
thus cannot transcribe miRNAs, it is currently thought that the platelets inherit their miRNA 
content during the shedding process from megakaryocytes.30 Thus, the platelet “miRNAome” 
in the circulation may provide insights into megakaryocyte function in the bone marrow. 
 
There are many more miRNAs encoded in the human genome than there are 
detectable in the circulation.31 For example, we detected >200 miRNAs using next 
generation sequencing (NGS) in plasma samples.32 Detectable miRNAs greatly vary in 
abundance. Not all miRNAs that are present in the circulation can be consistently quantified 
with cycle threshold (Ct) values of <32 by qPCR, even after pre-amplification. Another 
striking observation is the high correlation among the abundant circulating miRNAs.33 This 
may be due to their common platelet origin: in response to anti-platelet drugs, circulating 
levels of many miRNAs are reduced in platelet-poor plasma (PPP).34 Research into miRNAs 
is hampered by the current lack of functional miRNA data in bioinformatics resources. 
Access to cataloged experimental data is crucial to enable simple questions to be asked, 
such as “Which miRNAs are present in the circulation?”, as well as the ability to perform 
sophisticated pathway and network analyses.35 This lack of freely accessible data is being 
addressed by the addition of Gene Ontology (GO) annotations for cardiovascular-related 
miRNAs.36,37 In order to answer the question of circulatory miRNAs, we have created GO 
annotations for those miRNAs identified as being present in human plasma from our 
previous study.32 In the parlance of GO, the annotations were created using the GO term 
"extracellular space” (GO:0005615) with the addition of contextual information describing the 
extracellular space as part of blood plasma (using the Uber Ontology term 
Uberon:0001969). A large number of miRNAs were identified in PPP and platelet-rich 
plasma (PRP).32 For those with marked enrichment in PRP, as well as significantly 
increased levels in a platelet spike-in experiment, we were additionally able to include in the 
annotation that the miRNAs present in the extracellular space are likely to have originated 
from platelets (using the Cell Ontology term CL:0000233). In total, we have identified 230 
human miRNAs as present in the circulation and the annotations providing this information 
are available in the GO database.38 Inclusion of functional annotations such as these into 
public databases will enable researchers to find and analyze miRNA data more easily, 
allowing for faster progression of their research. 
 
YRNAs. In our most recent study, we have also identified YRNAs as another species 
of circulating non-coding RNAs that is platelet-derived.32 YRNAs are small non-coding 
RNAs, approximately 100 nucleotides in length, that are derived from 4 human genes 
(RNY1, RNY3, RNY4, RNY5 and about 900 pseudogenes).39,40 Using NGS in PPP and 
PRP, we observed a dominant peak at sequences of 32-33 nucleotides long, which was 
mapped to YRNA genes (Figure 2A).32 The full-length YRNAs have cytoplasmic or nuclear 
localization and are involved in the initiation of DNA replication as well as in ribosomal RNA 
quality control.41,42 They are components of Ro ribonucleoproteins, which constitute 
important autoantigens in autoimmune diseases such as systemic lupus erythematosus and 
Sjögren’s syndrome.43 YRNA fragments are present in the circulation, with 5’ fragments 
being much more abundant than 3’ fragments for the majority of RNY genes.32,44 YRNA 
fragments are generated during cell stress or apoptosis. Given that YRNA fragments are 
abundant in platelets, and strongly correlate to platelet-derived proteins (Figure 2B) and 
miRNAs in the circulation32, we speculate that the YRNA fragments are formed during the 
budding of platelets from megakaryocytes. In common with miRNAs, the YRNA fragments 
bind Ago proteins but do not seem to mediate target repression. However, in contrast to the 
processing of mature miRNAs from precursor miRNAs, YRNA fragments are generated by a 
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Dicer-independent mechanism.45 The predominant platelet origin of YRNA fragments in 
human plasma is further supported by the results from platelet spike-in experiments.32 
 
Ribosomal RNA. Ribosomal RNA (rRNA) is a key regulator of intracellular protein 
synthesis, and is also detected in the circulation. Tissue damage and unregulated cell death 
result in significant quantities of rRNA shifting into the extracellular compartment.46,47 As 
reviewed recently48, rRNA is thought to be able to act as a protein cofactor or template for 
enzyme rRNA. This may have several important pathophysiological roles in atherosclerotic 
plaques, including promotion of vascular hyperpermeability, initiation of coagulation and 
thrombus formation, recruitment of leukocytes, promotion of a pro-inflammatory phenotype 
of monocytes/macrophages, and promotion of cardiomyocyte death. The potential role of 
rRNA as a predictor of cardiovascular disease has not been addressed yet. 
 
Long non-coding RNAs. Recently, attention has shifted from small non-coding to 
long non-coding RNAs (lncRNAs). Unlike miRNAs and YRNAs, which are mainly found in 
the cytosol, lncRNAs are predominantly retained in the nucleus.49 This nuclear localization 
has important implications for their release mechanism. While miRNAs and YRNAs are 
secreted as part of any budding process of microvesicles with cytoplasmic components, 
even in the absence of injury, the secretion of lncRNAs may be dependent on cellular 
damage that is sufficient to release nuclear material. Upon release, the lncRNAs require 
protection from RNase degradation. In general, lncRNAs may be more susceptible to RNase 
activity than small non-coding RNAs as the longer sequence is more vulnerable to cleavage 
and not as easily complexed and protected by RNA-binding proteins. Whereas lncRNAs are 
readily detected in full blood, levels in plasma or serum tend to be low, at least in healthy 
individuals without tissue injury. The release of mitochondria-associated lncRNAs has been 
described in patients with myocardial infarction.50 It is possible that mitochondrial lncRNAs 
are protected from RNase degradation. Further, as cardiomyocytes are particularly rich in 
mitochondria, these lncRNAs may indeed be cardiac-derived. However, unlike troponins, 
lncRNAs are not cardiac-specific, so contributions from other cell types cannot be 
excluded.51 Since platelets are anuclear and have a low mitochondrial content, most 
lncRNAs may not be detectable in platelets, with the notable exception of circular RNAs 
(circRNAs). 
 
Circular RNAs. Recent evidence suggests that platelets are relatively abundant in 
circRNAs52, an emerging class of noncoding RNAs that had been described as early as 
1976.53 Development of advanced NGS techniques led to their recent rediscovery54, showing 
ubiquitous expression in both humans and mice.55 Several pathways exist to generate 
circRNAs.56 Most commonly, they are derived from exons of protein-coding genes through 
back-splicing, while some arise from intronic or intergenic regions via alternative 
splicing. circRNAs are generally localized in the cytoplasm, but how they are exported from 
the nucleus remains unknown. RNA-binding proteins like Quaking and Muscleblind are 
thought to affect the abundance of circRNAs in human cells through binding of the specific 
RNA-binding proteins to flanking intronic sequence motifs. Interaction between the RNA-
binding proteins on each end approximates both ends of the exon and facilitates the 
formation of a circle. Quaking regulates human circRNA biogenesis, and knockdown of 
Quaking decreases the expression of abundant circRNAs.57 CircRNAs were found to be 
enriched in platelets, where they are generated by exon back-splicing.52 Using RNase R to 
selectively remove linear transcripts, several distinct circRNAs were identified in the 
platelets. Although the majority of circRNAs are not cell type-specific, human platelets and 
erythrocytes were found to be highly enriched for circRNAs compared to nucleated cell 
types. Several circRNAs were expressed at much higher levels than the linear form of the 
RNA in platelets and erythrocytes. Interestingly, the relative proportion of circRNAs in 
cultured megakaryocytes is much lower compared to mature platelets. Combined with the 
finding that circRNA decays at a significantly slower rate than linear RNA, and platelets lose 
more than 90% of their progenitor mRNA, the enrichment of circRNA in platelets might be 
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the result of linear RNA degradation.52 This process has a profound effect on the 
composition of RNA, as anucleate platelets cannot transcribe new RNA. Recent reports 
demonstrated that circRNAs can serve as miRNA sponges, which are believed to negatively 
regulate miRNAs by sequestering miRNA molecules.58 This raises questions of how 
circRNAs interact with miRNAs and mRNAs in platelets, and how circRNA transcripts are 
formed in platelets. With their enrichment being a signature of mRNA decay, platelet 
circRNAs may reflect platelet function or ageing. 
 
The miRNA repertoire of platelets 
 
Landry et al first reported a large number of platelet miRNAs by using locked nucleic acid 
(LNA)-based microarray profiling.6 NGS has enabled the discovery of novel miRNA species. 
Plé et al identified nearly 500 species, with the let-7 family of miRNAs comprising nearly 
50% of the total.59 Since then, Bray et al have identified many more, bringing the total of 
recognized platelet miRNAs to around 750.4 The variation in reported platelet miRNA 
expression is not solely due to inter-individual differences such as gender and age.60 Sample 
preparation, storage, normalization procedures and measurement platforms play an 
important role. Studies aimed at defining the platelet miRNA profile use a variety of 
techniques, including micro-arrays, qPCR-based methods and NGS. For example, Wang et 
al demonstrated platform-associated amplification differences in miR-107, which showed 
much higher amplification with LNA-based assays compared to TaqMan assays.61 In clinical 
laboratory conditions, Yu et al showed upregulation of several apoptosis-related platelet 
miRNAs after prolonged blood bank storage of platelets.62 As platelet preparation from 
whole blood can lead to contamination with leukocytes and erythrocytes, themselves 
abundant sources of miRNAs, controlling cellular contamination of platelet preparations is 
essential.61 Variation in preparation and storage conditions can drastically affect platelet 
miRNA expression which may explain why inter-study miRNA expression ranks are highly 
variable. Based on the current literature, a combined inter-study miRNA expression rank list 
is presented in Figure 3. 
 
Association of platelet miRNAs with disease 
 
Antiplatelet drugs reduce the risk of cardiovascular events, but patients on antiplatelet 
therapy still suffer thrombotic events. Ever more potent antiplatelet strategies carry the risk 
of bleeding complications. Ideally, a “sweet spot” could be defined for each patient that 
offers maximum platelet inhibition with minimal bleeding risk.63 For optimal platelet inhibition, 
platelet turn-over is important: with a life span of 7-9 days, 10-15% of the platelet pool must 
be replenished every day, equivalent to 1010 - 1011 platelets per day.64 The platelet turnover 
rate may be important for the efficiency of drugs like aspirin with a short half-life. Aspirin 
irreversibly binds cyclooxygenase so is effective for the full lifespan of the platelet. However, 
increased platelet turnover can lead to more budding of new platelets without inactive 
cyclooxygenase between doses. Furthermore, newly formed platelets are larger, more 
reticulated, more reactive, and more prone to participate in thrombus formation compared to 
older platelets. They also contain a higher amount of RNA and are more able to produce 
proteins, in particular alpha granule proteins. Counting the subset of reticulated platelets 
may be a parameter for platelet turnover. However, the intrinsic properties of platelets could 
be even more important for platelet reactivity than their turnover rate.65 In light of the 
enrichment of miRNAs and circRNAs, and the described effects of mRNA degradation 
during the lifetime of platelets, the noncoding RNA content of platelets may better reflect 
their intrinsic properties.  
 
Platelet miRNA expression profiles in healthy volunteers remain stable over the life 
span of a platelet.66 This expression profile is significantly altered in various disease states 
including myocardial infarction67,68, diabetes69, and cancer.70 There is, therefore, the 
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opportunity to find new biomarkers or therapeutic targets, and increase our understanding of 
the pathophysiological mechanisms of these diseases. Anucleate platelets lack 
transcriptional control, so differences in miRNA signatures during platelet-activating disease 
states have been ascribed to a number of mechanisms: shedding of MPs71, synthesis of 
mature miRNA from precursor miRNAs69, and post-transcriptional modifications.59 We 
undertook the first systematic analysis of circulating miRNAs in a large population-based 
study (the Bruneck study) and revealed a loss of miRNAs in type 2 diabetes mellitus.72 
Subsequent studies indicated that this loss may be attributed to activation of calpain, which 
can affect platelet levels of Dicer.73 As this endoribonuclease is key in the processing of 
precursor miRNAs to mature miRNAs, its loss resulted in decreased levels of several 
platelet-enriched miRNAs.69,74 These findings are in line with studies showing that circulating 
miRNA changes in cardiovascular risk can be attributed to platelets.32,34 Additionally, we 
demonstrated that a combination of miRNAs may predict future cardiovascular events.75 
This has been confirmed by other investigators.76 In continuation of our work on circulating 
miRNAs in diabetes72, we have identified two angiogenic miRNAs as biomarkers for diabetic 
retinopathy.77  
 
Findings by other investigators and our group suggest that platelet miRNAs might not 
only reflect but also affect platelet function: 
 
miR-96 and VAMP8. In 2010, Kondkar et al reported a role for miR-96 in platelet 
reactivity.78 They showed that miR-96 may act through regulation of vesicle-associated 
membrane protein 8 (VAMP8), an important SNARE protein involved in platelet 
degranulation. Healthy volunteers’ platelets were categorized as either hyper- or hypo-
reactive. mRNA profiling revealed differential expression of a range of scripts, including 
VAMP8 mRNA (4.8-fold decrease in the hypo-reactive versus hyper-reactive platelets). This 
translated to a 2.5-fold lower VAMP8 protein expression in the hypo-reactive platelets. miR-
96 levels were upregulated in hypo-reactive platelets (2.6-fold higher). Transfection of 
VAMP8-expressing HCT cells with miR-96 was associated with dose-dependent reductions 
in VAMP8 mRNA and protein levels; a similar finding was reported in cells of a 
megakaryocyte lineage. miR-96 was predicted to bind the 3’ UTR of VAMP8. In contrast with 
this study, Shi et al reported no association between platelet response to clopidogrel and 
miR-96 expression, and miR-96 was not amongst the most highly expressed miRNAs found 
in human platelets.79 Although this does not discredit a role for miR-96 in regulating platelet 
reactivity, these findings need to be validated and explained in a larger study. 
 
MiR-376c, miR-599 and platelet phosphatidylcholine transfer protein. There is a 
racial disparity in survival in coronary heart disease between patients with Caucasian and 
Afro-Caribbean background, even after adjusting for all known factors. Edelstein et al 
investigated whether racial difference in platelet function underpins an increased thrombotic 
risk.80 154 healthy black and white volunteers were recruited and platelet reactivity to 
thrombin was measured. Higher aggregation and platelet calcium responses to PAR4 
(thombin receptor 4) in Afro-Caribbean individuals were found. Phosphatidylcholine transfer 
protein (PCTP)-encoding mRNA was found to be upregulated in Afro-Caribbeans. After 
profiling platelet miRNA signatures, 178 miRNAs, including miR-376c, were predicted to 
target PCTP mRNA. miR-376c levels inversely correlated with PCTP mRNA levels, PCTP 
protein levels, and PAR4 reactivity. miR-376c is part of a cluster of miRNAs differentially 
expressed by ethnic origin, which may underpin differences in platelet function. Interestingly, 
a statistical cluster of 24 miRNAs all mapped to chromosome 14q32.2. Among other 
differentially expressed miRNA were some of the most abundant platelet miRNAs: miR-223, 
-21, -23b, -107, and let-7c. Plé et al also found evidence of miRNA regulation of PCTP.59 
Their analysis predicted miR-599 targeting of the 3’UTR of PCTP mRNA, and showed 
downregulation of a reporter gene containing the PCTP 3’UTR in HEK293 cells transfected 
with pre-miR-599. 
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miR-223 and P2Y12 receptor expression. miR-223 is highly expressed in platelets 
and megakaryocytes, where it is thought to regulate thrombopoiesis. One of the most 
interesting features of miR-223 is its ability to bind to the 3’UTR of human P2Y12 receptor 
mRNA.6 The P2Y12 receptor mediates important platelet functions, including aggregation and 
granule secretion, and is activated by ADP, the physiological agonist of this Gi2 protein-
coupled receptor.81 Landry et al showed that platelet P2Y12 receptor mRNA co-precipitates 
with Ago2, suggesting that miR-223 could regulate receptor levels and thereby platelet 
function.6 Platelet response to ADP antagonists is clinically relevant given the widespread 
use of drugs such as clopidogrel, prasugrel, and ticagrelor in the prevention and treatment of 
myocardial infarction and ischemic stroke.  
 
Due to the proposed regulation of P2Y12 receptor function, miR-223 has been the 
focus of many clinically orientated studies. In particular, there is great interest in relation to 
platelet responsiveness to clopidogrel, a prodrug which requires hepatic cytochrome P450 
enzymes to become active. Shi et al reported decreased levels of platelet miR-223 in 
association with high platelet reactivity despite treatment with clopidogrel.79 They looked at 
patients presenting with non-ST elevation acute coronary syndrome, it terms of their platelet 
reactivity index, who were treated with aspirin and clopidogrel. In patients who had a 
reduced response to clopidogrel, platelet miR-223 was significantly downregulated, whereas 
miR-96 was unchanged. Platelet miR-223 also inversely correlated with the platelet reactivity 
index. Of note, neither miR-223 nor miR-96 was significantly different between normal and 
low responders when ADP-induced platelet aggregometry was used. These results suggest 
platelet miR-223 may be a predictor of normal and low responders to clopidogrel. This may 
be supported by the fact that P2Y12 mRNA can be found in Ago2 immunoprecipitates.6 
 
In a preliminary report including 21 males presenting with non-ST elevation acute 
coronary syndrome, Chyrchel et al studied miR-223 plasma levels. Patients were treated 
with aspirin plus either clopidogrel, prasugrel, or ticagrelor. Although there were no 
differences in plasma miR-223 levels between drug type, when all the data was pooled miR-
223 positively correlated with the level of platelet inhibition.82 These results seem in line with 
those of Shi et al who found that high platelet miR-223 levels predicted efficacious platelet 
inhibition with clopidogrel.79 Similarly, Zhang et al report decreased plasma miR-223 to be 
associated with clopidogrel “low-responders”.83 In this study of 62 patients with unstable 
angina, miR-223 was found to be the only independent predictor of low responders to 
clopidogrel, and was higher with greater degrees of platelet inhibition. 
 
miR-223 is also expressed in mouse platelets. In response to high agonist 
concentrations, miR-223 knock-out mice do not show any detectable alteration in 
aggregation, speed of clot retraction, platelet adhesion, or bleeding time. P2Y12 mRNA 
expression levels are also unchanged.84 This is probably due to mouse P2Y12 mRNA lacking 
the specific binding site for miR-223, rendering mouse models difficult to interpret in this 
context. Nonetheless, Elgheznawy et al subsequently demonstrated that miR-223 deletion in 
mice did result in modestly higher platelet activation at lower agonist concentrations.69 
Proteomic analysis revealed differential expression of kindlin-3 and coagulation factor XIII-A 
in platelets from miR-223 deficient mice.  
 
Zampetaki et al found that serum miR-223 levels are inversely associated with risk of 
future myocardial infarction, and showed a stronger association with fatal than non-fatal 
events.75 Badrnya et al showed reduced platelet microvesicle miR-223 in smokers.85 These 
findings are potentially complementary to those relating low platelet miR-223 level to 
increased P2Y12 activity in men, and to those showing higher platelet reactivity in response 
to miR-223 deletion in mice. Subsequent clinical studies have investigated platelet miR-223, 
including in a small cohort of patients who suffered an ischemic stroke. Duan et al report that 
platelet miR-223 and -146a were lower in stroke patients with diabetes versus controls.86 
Platelet miR-223 and -146a levels significantly correlated with platelet reactivity as 
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measured by P-selectin expression and also correlated to plasma levels, suggesting that 
platelets are a major source of circulating miR-223.   
 
In summary, miR-223 targets the 3’UTR of the human P2Y12 platelet receptor mRNA. 
The P2Y12 receptor is important in platelet activation and is the target of many drugs used to 
inhibit platelet function. Lower levels of platelet miR-223 therefore may result in more P2Y12 
receptor activity and thus higher platelet reactivity. In this way, lower platelet miR-223 levels 
may increase the risk of thrombotic disease such as myocardial infarction. This also may 
underpin the observation that lower platelet miR-223 levels are associated with reduced 
efficacy of P2Y12 receptor antagonists such as clopidogrel. Mice lack the specific miR-223 
binding site on the P2Y12 mRNA and so comparisons to human data is difficult. Nonetheless, 
miR-223 deficient mice do seem to have altered platelet function, perhaps through regulation 
of other platelet proteins involved in clotting.      
 
 miR-126 and ADAM9. Changes in circulating miR-126 may also reflect platelet 
activity rather than endothelial dysfunction. Early studies, including one from our group72, 
stated that miR-126 is endothelial-specific. Whereas miR-126 is enriched in endothelial cells 
and supports endothelial integrity, its circulating levels cannot be attributed solely to 
endothelial cells. In fact, megakaryocytes and endothelial cells both express miR-126, and 
circulating miR-126 levels appear to be predominantly platelet-derived.34,77 
 
De Boer et al investigated the effects of aspirin on the platelet contribution of 
circulating miR-126 in patients with type 2 diabetes. PRP from subjects was treated with 
either arachidonic acid (a platelet activator), or, arachidonic acid plus apsirin. Once the PRP 
had been treated it was centrifuged to separate the platelets from the now platelet-poor 
plasma. Platelet activation resulted in a considerable transfer of miR-126 to the PPP fraction 
and this could be rescued with the addition of aspirin. miR-223, -16, and -423 showed a 
similar pattern suggesting that they are all relased from platelets upon activation and that 
aspirin attenuates this release. miR-126 levels also correlated with platelet activation as 
measured by soluble P-selectin. As part of another clinical trial involving patients with type 2 
diabetes, the platelet activation state (measured via P-selectin expression) was assessed in 
40 patients treated with increasing doses of aspirin. Platelet activation positively correlated 
with plasma miR-126 and aspirin reduced circulating levels of miRNA-126. Arguing against 
an endothelial origin of miR-126, the authors point out that aspirin primarily inhibits platelet-
enriched COX-1, whereas the endothelium predominatly expresses COX-2. They also 
demonstrated no change in circulating von Willebrand factor.87 Taken together, these 
findings suggest that aspirin has the potential to significantly alter the miRNA signature of 
plasma and careful consideration should be given when designing clinical studies in pursuit 
of novel biomarkers. 
 
In our experiments, we demonstrated that plasma miR-126 levels 1) correlate to 
platelet MPs, 2) are reduced upon platelet inhibition and 3) are associated with markers of 
platelet activation in the general population.32 These associations were further substantiated 
by genetic evidence. The single nucleotide polymorphism (SNP) rs4636297 is located in the 
primary transcript-encoding region of miR-126 and affects its processing to mature miR-126. 
The minor allele is associated with increased processing of the primary miRNA to mature 
miR-126. In a population-based study, carriers of the minor allele had higher levels of miR-
126 in plasma and in serum.32 The increase in circulating miR-126 was associated with a 
rise in platelet activation markers such as platelet factor 4 and pro-platelet basic protein. The 
genetic data on miR-126 and platelet function were in line with findings in the Bruneck 
cohort, in which miR-126 serum levels were positively associated with risk of myocardial 
infarction after adjustment for miR-223 and miR-197, again with platelets being identified as 
the most probable source.75 A study by Yu et al showed that higher plasma miR-126 
predicted major adverse cardiac events in 491 patients after a percutaneous coronary 
intervention, while on dual antiplatelet therapy.88 
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In mice, inhibition of miR-126 by antagomiRs (synthetic inhibitors of miRNAs) 
decreased thromboxane A2-dependent platelet aggregation. This effect is likely due to 
megakaryocyte miR-126, but since antagomiRs are administered systemically, the 
contribution of other cell types, in particular endothelial cells, cannot be excluded. However, 
inhibition of miR-126 expression in endothelial cells would be expected to result in 
endothelial dysfunction and increased platelet activation. Similarly, if the effects of the SNP 
rs4636297 were limited to endothelial cells, one might expect that higher miR-126 levels are 
protective for endothelial cells and thus reduce platelet activity. The opposite was observed 
in mice and men. In MEG-01 cells, a human megakaryocyte cell line, ADAM 
metallopeptidase domain 9 (ADAM9) was confirmed as a direct miR-126 target that 
attenuates the adhesion of platelets to collagen. Inhibition of miR-126 by antagomiRs also 
had indirect effects on P2Y12 expression levels, at least in mice. Thus, in addition to 
endothelial cells, miR-126 affects megakaryocytes. It remains to be seen whether platelet-
specific deletion of miR-126 can recapitulate the accelerated atherosclerosis phenotype 
seen in miR-126-deficient mice.89 
 
In summary, higher plasma or serum levels of miR-126 are associated with an 
increased risk of myocardial infarction and other major adverse cardiac events. This may, at 
least in part, occur via increased platelet activation. Inhibition of miR-126 with antagomiR-
126 reduces platelet activation in mice, which may be explained by blocking of ADAM9’s 
negative effect on platelet:collagen adhesion or via indirectly affecting platelet P2Y12 
expression levels. 
 
Cellular crosstalk via miRNAs? 
 
Several studies suggest that secreted miRNAs may act as paracrine mediators. The 
concept is appealing, but most evidence is currently limited to in vitro studies. By 
overexpressing a miRNA in one cell type, harvesting microvesicles from the conditioned 
media and adding these microvesicles to recipient cells, miRNA transfer and downregulation 
of miRNA targets is detectable, suggesting that the miRNA uptake has biological function. 
There are several caveats to these in vitro studies: 
 
1) MiRNAs are not very abundant in the circulation and pre-amplification is usually 
required for all but the most abundant miRNAs for reliable detection by qPCR. It is 
difficult to envisage how the few copy numbers of miRNAs would have a potent effect 
on target gene expression. The amount of circulating miRNAs is several orders of 
magnitude below the cellular miRNA content, and exogenous miRNAs would have to 
compete with the endogenous miRNAs in the recipient cells for loading into the RNA-
induced silencing complex. Unless there is a receptor that recognizes miRNAs and 
initiates a downstream signaling cascade, it is difficult to envisage how uptake of 
exogenous miRNAs could mediate biological effects. 
2) MPs and exosomes are rich in proteins. The protein content of microvesicles may be 
functionally more important than their miRNA load. RNase treatment does not 
unambiguously prove that the observed biological effect is due to miRNAs. Protein 
degradation may also occur during the RNase digestion step. 
3) In situ hybridization studies for a particular miRNA tend to reveal a characteristic 
staining pattern. For example, staining for miR-126 is confined to endothelial cells, 
whereas staining for miR-143 and miR-145 is observed in vascular smooth muscle cells. 
If miRNA transfer were a common phenomenon, such specificity would not be detected, 
and a more homogenous staining pattern would be expected.  
4) Importantly, the tissue architecture, including basement membranes and extracellular 
matrix, should act as a physical barrier for the exchange of microvesicles. 
5) Routine cell culture uses fetal calf serum, which is a source of microvesicles. 
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Thus, we currently lack convincing evidence that the exchange of miRNAs is more than an 
in vitro phenomenon. In uninjured tissues, the cellular miRNA exchange might be low. It is 
conceivable that a miRNA transfer could occur under pathological conditions, such as 
platelet activation and clearance by inflammatory cells. Several experiments shed light on 
the role of platelet miRNA as a putative paracrine regulator of cellular function via regulation 
of others cells’ mRNA and protein expression. For abundant platelet miRNAs, such as miR-
223, target genes have been described, many of which are associated with inflammation. 
This miRNA is also expressed in leukocytes, further indicating a potential role. Given that 
platelets are already heavily implicated in several disease processes with an inflammatory 
basis, an interplay between endothelial cells, leukocytes, monocytes, and other cells types 
by endogenous and transferred miRNA seems plausible and an important area for further 
investigation. 
 
Jansen et al sought to define the miRNA content of circulating microvesicles and 
vesicle-free plasma in 181 patients with stable coronary artery disease undergoing coronary 
angiography.90 Over 6 years follow-up, microvesicle miR-126 and miR-199a levels above the 
median were associated with significantly fewer major adverse cardiac events and 
percutaneous coronary interventions. There was no association between miRNAs from PPP 
and cardiovascular events. Microvesicle miR-126 was significantly reduced, and 199a 
trended towards reduction, in coronary artery disease patients versus age-matched controls. 
Again, no such difference was found in the PPP. Through microvesicle typing of surface 
markers, they established that miR-126 expression is highest in CD31+/CD42b- 
microvesicles (i.e. endothelial), consistent with known expression patterns in endothelial 
cells, and miR-199a is highest in CD31+/CD42b+ microvesicles (i.e. megakaryocyte-derived). 
These results are in contrast to results for circulating miR-126 levels. However, this study by 
Jansen et al looked specifically at the microvesicular compartment, making cross-study 
comparisons difficult.  
 
Laffont et al showed that activated platelets can deliver regulatory Ago2-
miRNA complexes to endothelial cells, and that this occurs via MPs. First, they confirmed 
that activated platelets release substantially more MPs than quiescent platelets. Profiling the 
miRNA content of the MPs showed that the miR-223 content was greatly increased after 
platelet activation, suggesting selective packaging of miRNAs into platelet MPs. They then 
showed that the MPs contain functional Ago2:miR-223 complexes which could cleave a 
complementary miR-223 RNA sensor, suggesting these complexes are functionally relevant. 
Next, they used fluorescently labeled MPs to demonstrate internalization by human umbilical 
vein endothelial cells. Endothelial miR-223 levels increased 22-fold after incubation with 
MPs for 1 hour, an effect which persisted for 48 hours. Again addressing functional 
relevance, endothelial cells demonstrated a 44% reduction in a transfected reporter gene 
under miR-223 control when incubated with MPs. Significant downregulation of endogenous 
RNA levels occurred within 6 hours of exposure to platelet MPs, an effect which was 
rescued with the addition of a miR-223-neutralizing “sponge”.17 
 
Pan et al also showed increased MP release and MP miRNA enrichment after 
platelet activation. In the apolipoprotein E null mouse model of atherosclerosis, MP miR-223 
content was higher than in controls. This finding was also tested in a small selection of 
human patients, in whom miR-223 expression was higher in platelets and MPs of patients 
with inflammatory diseases compared to healthy controls. The authors demonstrated that 
endothelial cells take up MPs in an ATP-dependent manner, and endothelial miR-223 levels 
increase without an increase in pre-miR-223, suggesting that the increase was not due to de 
novo synthesis in recipient cells. Both a miR-223 mimic, and incubation with MPs, were 
shown to reduce insulin-like growth factor 1 receptor protein levels. This effect was blocked 
by anti-miR-223. miR-223 delivery increased advanced glycation end products-induced 
apoptosis, potentially via reduced levels of the insulin-like growth factor 1 receptor.91 
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Finally, Gidlöf et al showed that patients with ST-elevation myocardial infarction had 
reduced levels of miR-22, -185, -320b, and -423-5p in platelets compared to controls, and an 
even greater reduction in aspirated coronary artery thrombus.67 The authors concluded that 
this is due to platelet activation and miRNA release. In vitro they demonstrated miR-22, -
185, -320b, and -423-5p release into the supernatant after thrombin-induced platelet 
activation. Using platelets transfected with a scrambled, fluorescently labeled miRNA, they 
showed effective transfer to endothelial cells when incubated with activated platelets. 
Furthermore, this was shown to be MP-dependent as the addition of brefeldin A (a vesicle 
formation inhibitor) prevented miRNA transfer. Overexpression of miR-22 and miR-320b in 
endothelial cells suggested these miRNAs were involved in the regulation of intercellular 
adhesion molecule 1 (ICAM1). When endothelial cells were incubated with platelet 
releasate, ICAM1 expression was downregulated by 30%. Knockdown of endogenous 
endothelial miR-22 and miR-320b caused an increase in ICAM1 expression, confirming that 
the effect was due to MP miR-22 and/or miR-320b. Interestingly, this could be rescued by 
incubating the cells with platelet releasate.  
 
In summary, there is now good evidence that 1) platelets transfer miRNA, and 2) that 
this is mediated by MPs.92,93 However, it is less certain whether this transfer is functionally 
relevant at physiological concentrations in vivo and to what extent the observed effects are 
mediated by the miRNA content rather than the protein content of the platelet MP material. 
Although most studies have focused on platelet transfer of miRNA to endothelial cells, 
Risitano et al showed that RNA transfer can occur between circulating platelets and 
monocytes.71 
 
Guidance on how to measure circulating miRNAs 
 
Research on circulating miRNAs is attracting increasing attention, as non-coding 
RNAs may constitute an entirely new entity of biomarkers. A prerequisite for advances in this 
area is the generation of comparative data by independent groups. To help this we have 
suggested a set of minimum reporting standards and recommended methods for circulating 
miRNA data (Table 1). 
 
Plasma or serum? A fundamental question is the choice of plasma or serum for 
measuring miRNAs (Figure 4). The origin of miRNAs in plasma and serum may not be the 
same, as platelets are activated during clotting and may contribute a larger proportion of 
miRNAs compared to plasma. In plasma, the cells are removed by centrifugation in the 
presence of an anti-coagulant. Citrate and EDTA are the preferred anticoagulants. Heparin 
plasma, for the reasons outlined below, is less suitable for miRNA measurements. Platelet 
activation during plasma centrifugation is another concern. Serum, on the other hand, is 
obtained by clotting blood at room temperature for 30 min to 1 h. The clotting process 
involves the activation of thrombin, which cleaves fibrinogen to fibrin. Thrombin is a protease 
and its substrate specificity is not restricted to fibrinogen. The coagulation cascade involves 
a series of proteases, which may degrade carrier proteins of miRNAs. This might result in a 
loss of miRNAs, which can be mitigated by adding RNase inhibitors.94 If platelets release 
miRNAs upon activation, then findings in plasma and serum might give opposite results: 
plasma miRNAs may reflect the platelet release prior to blood sampling, whereas serum 
miRNAs may reflect the extracellular and platelet miRNA content combined - the more 
release, the less content. Thus, for our most recent studies, we used PPP, which we believe 
to be the best samples for linking miRNAs to in-vivo platelet activation. 
 
Platelets, microvesicles, and exosomes. An understanding of which specific 
fraction of the circulation is being measured, is of the utmost importance for reproducibility 
and adequate inter-study comparison. Ideally, one would be able to easily separate different 
circulating compartments: the cellular compartments (erythrocytes, leukocytes, platelets), 
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the microvesicle compartment, the exosome compartment, and the particle-free 
compartment devoid of membrane-bound vesicles or cells. Whilst isolating erythrocytes and 
leukocytes is relatively easy based on their size and density, isolating the smaller and less 
dense compartments poses a greater challenge. Isolating platelets from platelet-rich plasma 
is done routinely but requires care in order to avoid activating the platelets during the early 
centrifugation steps. As platelets release microvesicles upon activation, this could affect the 
measured miRNAs in platelets as well as plasma. 
 
Residual platelets. Platelets contain a substantial amount of miRNAs and are likely 
to be major contributors to the circulating miRNA pool, as discussed above.34 This further 
complicates sample preparation for miRNA analysis: differences in plasma preparation, 
centrifugation speed, duration of coagulation and the residual platelet content will have 
impact on multiple miRNAs.95,96 In RNA extracts from plasma samples, the detection of the 
platelet- and megakaryocyte-specific transcript Integrin alpha-IIb can be used to assess 
platelet content. Notably, the expression of Integrin alpha-IIb correlates with the expression 
of abundant platelet-derived plasma miRNAs (miR-24, -126, -191, -223). If plasma samples 
have a very high residual platelet content, their miRNA profile may be more similar to serum 
and reflect predominantly platelet miRNA content rather than platelet miRNA release. 
Plasma platelet content must be uniform to allow comparisons between samples, as residual 
platelets may introduce confounding. When plasma samples have already been collected, 
an additional centrifugation prior to RNA extraction may reduce the platelet content.95 
However, centrifugation of plasma after freezing is still subject to the risk of contamination 
from platelets lysed during the freeze/thaw cycle. Ideally, a method for the preparation of 
PPP prior to storage should be used to minimize the effect of residual platelets on miRNA 
measurements. 
 
Hemolysis. Erythrocytes are the most abundant cell type in blood. The rupture of 
erythrocytes can occur due to high shear forces in the needle during blood collection or 
improper handling during sample processing. As hemolytic samples contain a high amount 
of red-blood cell-derived miRNAs, the levels of multiple miRNAs are altered in hemolytic 
samples.97 Hemolysis can be assessed in plasma and serum by measuring hemoglobin 
spectrophotometrically or in the respective RNA extracts by analyzing miRNAs known to be 
affected by hemolysis such as miR-451.98 It is advisable to exclude hemolytic samples from 
further analyses. Alternatively, such compromised samples can only be used for miRNAs of 
interest that are unaffected by hemolysis.99 
 
Leukocyte contamination. Cells shed miRNAs via MPs and exosomes into the 
extracellular space. The miRNA content of the MPs and exosomes differs depending on the 
stimulus of the parent cells. However, the intracellular concentration of miRNAs is much 
higher than in plasma or serum. Considering the very low concentration of extracellular, 
circulating miRNAs, any contamination of plasma or serum samples with cellular material, 
for example leukocytes, will greatly affect the miRNA profile. Thus, studies reporting a 
surprisingly large number of circulating miRNAs compared to other publications may have 
analyzed samples that were contaminated with cellular material. 
 
Batch effects. Batch effects can occur when analyzing the expression of miRNAs on 
multiple qPCR plates. In order to minimize their impact, several precautions should be taken 
to obtain reliable data: 1) To correct for variability between plates, a calibrator sample should 
be included across all plates. 2) The same batch of plasticware and reagents such as PCR 
Mastermix, primers and probes should be used for the entire study cohort. We have 
previously observed lot-to-lot-variability for miRNA reagents, even from leading 
manufacturers. 3) Reagents should be aliquoted, as freeze-thaw cycles affect their quality 
and performance. 4) Samples from different groups should be distributed equally across all 
batches. These precautions minimize the impact of batch effects and help to obtain more 
reliable data. 
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Endogenous normalization controls. Normalization procedures should eliminate 
technical and experimental variation across samples in order to more reliably identify 
biological differences. In qPCR analysis, normalization controls are used to correct for 
variability in RNA extraction, reverse-transcription and PCR. Ideally, a normalization control 
is stably expressed and not affected by experimental conditions or clinical parameters. For 
the analysis of miRNAs in cells or tissue, small nucleolar RNAs (snRNAs) are routinely used 
to normalize data. In general, they accurately reflect the small RNA content of a sample, 
although there are limitations and drawbacks. For example, snRNAs can correlate with 
cancer pathology and prognosis which can introduce bias when they are used as 
normalization controls for cancer samples.100 For circulating miRNAs, however, there is no 
generally accepted endogenous control. snRNAs are intracellular RNA molecules and their 
levels in the circulation are very low. U6 RNA has been used as a normalization control in 
plasma and serum samples but circulating levels of U6 display inter-individual variability and 
are affected by inflammatory processes, reducing its reliability.101 Single miRNAs or panels 
of miRNAs have been used or suggested as endogenous controls: MiRNAs that have been 
used as normalizers include miR-16, miR-21, miR-93, miR-103, miR-191, miR-192, miR-423 
and miR-425. These miRNAs, however, may well be affected by other uninvestigated 
diseases or medications. Anti-platelet therapy, for example, has been demonstrated to lower 
the circulating levels of plasma-derived miRNAs including miR-21 and miR-191.34 
Alternatively, data can be normalized to the average Ct of multiple or all analyzed 
miRNAs.102 Generally, combinations of miRNAs may be a more robust approach, based on 
the assumption that overall miRNA expression is stable and not affected by disease to the 
same degree as individual miRNAs. The more miRNAs that are combined, the more robust 
the control should be. However, this normalization method can be problematic when several 
of the miRNAs used to normalize are dysregulated in a similar direction, potentially causing 
false-positive or -negative findings. Therefore, accepting that no better endogenous 
alternatives exist, neither a single miRNA nor a combination of miRNAs represent the 
“perfect” normalization control. 
 
Exogenous normalization controls. The most commonly used normalization 
method for circulating miRNA analysis is the use of an exogenous “spike-in” control. For this 
purpose, synthetic oligonucleotides of miRNA sequences from other species are used, 
typically from the nematode Caenorhabditis elegans (e.g. Cel-miR-39). Such spike-in 
controls are added in equal amounts to each sample during RNA extraction or reverse 
transcription. A spike-in control added at the RNA extraction step can normalize for 
differences in extraction efficiency, reverse transcription or qPCR efficiency, which may be 
caused by the presence of inhibitors in the sample or pipetting errors. Spike-in controls 
generally reflect miRNA quantities in different samples, but we have observed that RNA 
samples display a lower quantity of Cel-miR-39 when they were stored at -80°C for a longer 
period of time, impairing analysis in older samples. Moreover, heparin medication can affect 
Cel-miR-39 as well as the measurement of miRNAs, depending on their origin.103,104 The 
Cel-miR-39 measurements across samples must be stable. Variability exceeding 0.5-1 Ct 
values should be cause for concern. 
 
MiRNA measurements. The gold standard for miRNA measurements is qPCR. It 
provides independent and robust amplification and quantitative detection of minute RNA 
amounts across the wide dynamic range of miRNA expression levels. Among the drawbacks 
of the technology is the fact that its high-throughput capabilities are limited. We have 
previously compared commercial qPCR assays and obtained good agreement between 
assays from two suppliers, for individual Taqman miRNA assays and customized qPCR 
plates from Exiqon. For customized qPCR plates, however, there is the possibility that 
variations in the manufacturing process remain undetected. This is less likely to occur in 
standard miRNA assays as multiple users will rapidly detect manufacturing problems. Thus, 
it is important to know the expected measurement range for miRNAs of interest when using 
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customized qPCR plates, and to compare the results from each batch of customized qPCR 
plates with individual qPCR assays.  
 
We and others have noted difficulties comparing miRNA measurements from 
different technologies. In particular, there is poor agreement between microarrays and 
qPCRs when assessing quantitative changes. Microarray-based technologies use 
hybridization and are suitable for detecting the presence of miRNA species, but have limited 
quantitative accuracy and dynamic range. Similarly, NGS has several drawbacks, in 
particular requiring much larger sample volumes than qPCR analysis, and the introduction of 
amplification bias for certain miRNAs during library preparation. For example, in our study 
we obtained most reads for miR-486, a miRNA that is present in the circulation but has a 
relatively high Ct value by qPCR, suggesting it is much less abundant than other circulating 
miRNAs. Thus, miRNAs with more sequencing reads are not necessarily more abundant 
(Figure 5). Quantitative comparison must only be made by comparing sequencing reads for 
the same miRNAs.  
 
Freedman et al used high-throughput microfluidic quantitative PCR to analyse the 
miRNA signature in blood (whole blood, platelets, mononuclear cells, plasma, and serum) 
collected from 5 healthy individuals. They screened for 852 miRNAs in 83 patients 
undergoing diagnostic coronary angiography and categorised their patients into two groups: 
with coronary artery stenosis ≥70% (n=34) and without (n=49). Increased plasma expression 
of miR-494, miR-769-3p and miR-490-3p was associated with ≥70% coronary stenosis and 
logistic regression analysis found anti-hypertensive therapy, smoking and miR-769-3p were 
significantly associated with coronary status.105 The very low correlation of the most 
abundant platelet miRNAs found in this study is striking. Only one of the commonly reported 
highly expressed miRNAs (miR-92a) was detected. It is likely that there are similar 
discrepancies with plasma miRNA measurements. One cause for this difference may be the 
high-throughput BioMark Real-Time Fluidigm PCR system used in this study to increase the 
number of miRNA measurements that can be performed simultaneously, as no validation by 
conventional qPCR was provided. 
 
Potential for Clinical Translation 
 
The miRNA biomarker field is currently nascent. While there is much to link the 
expression of miRNAs to various diseases, the clinical utility or validity of miRNA detection 
has not been demonstrated. Currently, miRNAs are manually extracted, presenting the 
largest obstacle to increasing throughput. If new technological platforms provide the 
opportunity for faster miRNA extraction or direct analysis of miRNAs without the need for 
miRNA extraction, they will significantly improve the “ease-of-use” in clinical settings. 
Increasing throughput, however, must not compromise the quantitative accuracy of the 
analysis for both low- and high-abundance miRNAs. Ideally, miRNA measurements need to 
be able to out-perform current diagnostic methods to reach the clinical mainstream. 
 
In addition to current practical limitations, miRNA biomarkers will also need to be 
presented in the context of related miRNAs in order to be adequately interpreted. There are 
relatively few tissue-specific miRNAs, with miR-122 being an exception given its exquisite 
liver specificity.106 We recently showed that high circulating miR-122 levels are associated 
with an adverse lipid profile, and predict development of metabolic syndrome and diabetes 
mellitus type 2.107 However, most circulating miRNAs are ubiquitously expressed and 
numerous cell types can release miRNAs. This complicates its clinical application, as levels 
of individual miRNAs can greatly vary between patients, without any pathological 
significance. Therefore, it is crucial to represent relative expression levels of a miRNA in 
relation to a network of several other miRNAs. The use of a so-called “miRNA signature” can 
greatly strengthen the predictive and diagnostic value. 
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As the origin of many plasma miRNAs is unknown, De Rosa et al investigated trans-
coronary gradients of various miRNA in patients with acute coronary syndrome in a bid to 
define coronary-specific changes in the setting of myocardial damage. Samples were taken 
from the aorta and coronary sinus. They found an upregulation of the muscle-enriched miR-
499, -133a, and -208a in acute coronary syndrome patients, of which miR-499 correlated 
with troponin levels, an established clinical marker of myocardial damage. Contrary to their 
predictions, miR-126 decreased across the coronary circulation, despite its high expression 
in endothelial cells. They also described a negative trend for miR-223 across the coronary 
circulation in the acute coronary syndrome group but not in the stable coronary artery 
disease group; however this did not reach statistical significance.108 An alternative 
explanation for the reduction in miR-126 and miR-223 across the coronary circulation is the 
retention of platelets and platelet MPs in the affected myocardium, or differential activation of 
platelets in venous and arterial settings. 
 
Pharmacological inhibitors can be used to identify the cellular origins of miRNAs. By 
comparing plasma miRNA levels in the same individuals before and after initiation of anti-
platelet therapy, we identified a set of plasma miRNAs that is responsive to anti-platelet 
therapy.32 The miRNA candidates were abundant in platelets, but they were not platelet-
specific. Moreover, not every abundant platelet miRNA was equally affected by anti-platelet 
medication. Some miRNAs, despite their abundance in platelets, may be expressed at 
higher levels in other cell types. Consequently, their plasma levels may be less dependent 
on platelets. Given the platelet origin of many abundant miRNAs, it is not surprising that the 
same miRNAs are deregulated in multiple diseases. The question, however, remains 
whether the circulating miRNA changes are cause or consequence. In cancer, for example, 
many of the miRNA alterations may be due to platelet activation, rather than the release of 
miRNAs from tumor tissue.  
 
Early studies compared platelet samples from different individuals. Longitudinal 
sampling eliminates inter-individual variability. For example, using serial measurements 
before and after anti-platelet medication, we investigated the effect of 10mg prasugrel 
followed by the addition of an escalating aspirin dose regimen (75mg daily in week 2, 300mg 
daily in week 3) on the PPP miRNA signature of healthy young volunteers. Using custom 
made miRNA qPCR plates, 92 targets were measured at four different time points. 
Antiplatelet therapy was associated with a reduction in plasma miR-223, -126, -15, -191, -
20b, -21, and -24. The findings were replicated in plasma of patients with recent 
symptomatic carotid atherosclerosis who had begun treatment with dipyridamole or 
clopidogrel, in addition to aspirin. These patients showed a reduction in miR-223, miR-126, 
miR-150, and miR-191.34 The effect was less pronounced, presumably because the 
symptomatic patients were on aspirin medication at baseline and the follow-up measurement 
was only taken after 48 h. The reduction in platelet miRNAs upon platelet inhibition 
complements previous findings by Zampetaki et al in an ischemia/reperfusion injury model 
by thigh cuff inflation, in which plasma platelet miRNAs increased upon platelet activation.75 
 
 The clinical use of platelet function tests is limited at present, despite clear 
differences in response to pharmacological platelet inhibition. In the case of clopidogrel, a 
pro-drug, a large percentage of this variation can be attributed to different cytochrome P450 
isoforms involved in its bioactivation.109 However, this in itself does not explain all of the 
variation in efficacy. Measurements of platelet activity by light transmission aggregometry is 
considered the gold standard, but this test is performed ex vivo and not well standardized 
between laboratories. Vasodilator-stimulated phosphoprotein (VASP) phosphorylation and 
VerifyNow P2Y12 assays measure platelet activation in full blood but only in response to a 
single pathway, ADP stimulation. Platelet miRNAs may offer an opportunity to obtain an 
alternative read-out for platelet activation in vivo that integrates activation by multiple 
agonists rather than just ADP (Figure 6). Platelet miRNA measurements, however, will only 
be useful if they provide diagnostic advantages. They also must be easy to perform, and 
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capable of discriminating the degree of inter-individual variability in platelet inhibition or 
platelet turnover. 
 
 
Conclusions 
 
Initially, circulating miRNAs were thought to originate from tissue injury. This is indeed the 
case for cardiac miRNAs that are released after myocardial infarction akin to troponins. For 
basal miRNA levels, however, the importance of circulating cells is now apparent, and the 
contribution from anucleate cells such as erythrocytes and platelets must not be 
underestimated. Several challenges face the accurate detection and use of plasma and 
serum miRNAs:  
 
(1) Variability in samples’ cell composition affects miRNA profiles. This includes anuclear 
cells such as erythrocytes and residual platelets. Pre-analytical variation in sample 
preparation or handling must be minimized to avoid alterations of results. Given the platelet 
origin of many abundant miRNAs in plasma and serum, the use of PPP would seem to be 
the most appropriate substrate for miRNA measurements. In conventional plasma samples, 
the number of residual platelets can vary. Also, without inhibitors, platelet activation may 
occur during centrifugation. In serum, the stability of miRNAs may be affected, and miRNAs 
may be trapped in the clot. This could introduce bias that affects results, in particular if the 
clotting time varies between sampling.  
 
(2) The concentration of extracellularly circulating miRNAs is very low, and the miRNA yield 
of plasma and serum is insufficient for conventional quality control methods, such as optical 
densitometry or Bioanalyzer. Generally, equal volumes of plasma and serum are used for 
extraction. No correction is performed for RNA content. This approach of normalizing by 
volume is, however, analogous to protein measurements. In both cases, the total RNA or 
total protein amount of plasma would not be a suitable normalization control for the miRNA 
or protein biomarker of interest.  
 
(3) Currently, there is no endogenous control for the normalization of circulating miRNAs. 
Instead, exogenous spike-in controls are used for normalizing the extraction procedure. The 
values of spike-in controls such as Cel-miR-39 relate entirely to the consistency of the 
isolation procedure, not to the starting RNA quantity. By measuring a broader panel of 
unrelated miRNAs, the mean Ct value can be used for normalization.  
 
(4) MiRNAs in plasma and serum are highly correlated. Assessing individual miRNAs 
without integration into a wider miRNA network is of limited utility. Relative changes in 
miRNAs to one another (so-called “miRNA signatures”) can be more informative than the 
changes of individual miRNAs.  
 
These points will need to be addressed in future publications on miRNA biomarkers in order 
to facilitate comparability between studies, something that has been difficult with variations 
between measurement platforms and lack of guidelines for standardization. Standardized 
miRNA measurement platforms are currently under development, which could reduce 
measurement variability, whilst facilitating cross-study comparisons. In addition to the need 
for consensus on sample preparation and analytical procedures, future research will need to 
move on from reporting on single miRNAs and focus more on miRNA signatures. However, 
these issues are not insurmountable, and once addressed, future studies can further 
evaluate the potential of miRNA biomarkers for clinical use and whether miRNA assays will 
outperform existing clinical measurements. 
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Table 1. Minimum reporting standards and methodological recommendations for the 
analysis of circulating miRNAs. 
 
Minimum reporting 
standards Recommendations 
1. Phlebotomy protocol  
Sample venous blood using butterfly or regular blood 
collection needle; standardize relevant pre-analytical 
variables (e.g. fasting, smoking, exercise) 
2. Anticoagulant used Use citrate or EDTA; avoid heparin due to interference with qPCR   
3. Time until processing Complete sample processing within 2 hours from sampling to minimize variability and degradation 
4. Sample processing 
Perform an initial soft spin to collect plasma, followed by a 
faster platelet depletion spin with added inhibitors of platelet 
activation. 
5. Sample storage Store samples at -80°C, avoiding freeze-thaw cycles prior to analysis. 
6. RNA protocol 
Use a validated miRNA or total RNA extraction kit; use a 
carrier (MS2 protein or glycogen); avoid potential batch 
effects by co-isolating RNA from across compared groups. 
7. miRNA measurement 
platform 
Avoid batch effects of different technical lots for used 
laboratory material and equipment 
8. Average Ct levels for 
each assay 
Assays with an average Ct value >32 (when using a 40-
cycle protocol) should be avoided. Report average values to 
facilitate adequate interpretation of presented fold changes. 
9. Variability of the 
normalization 
reference 
Across-sample variability of quality control markers such as 
an exogenous spike-in miRNA should be no more than 1-2 
PCR cycles 
10. Normalization 
method(s) 
Normalize to the average Ct value of multiple assays or to 
an exogenous spike-in control. 
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Figure legends 
 
Figure 1. Overview of non-coding RNAs in platelets. Although platelets are anucleate, 
they contain genetic material in the form of non-coding RNAs. These include small non-
coding RNAs, such as microRNAs (miRNAs) and YRNA fragments as well as long non-
coding RNAs, such as circular RNAs (circRNAs). Secondary structures of RNA sequences 
were predicted using RTips. 
 
Figure 2. Small non-coding RNAs in plasma. A) Two peaks corresponding to miRNAs 
and YRNAs were observed by small RNA sequencing in plasma. B) Correlation of YRNA 
fragments to plasma levels of platelet factor 4 (PF4), pro-platelet basic protein (PPBP), and 
P-selectin (SELP). Lipocalin 2 (LCN2) was used as control. N=667.  
 
Figure 3. Platelet miRNA levels. Relative abundance of miRNAs in platelets were reported 
in 8 studies (indicated by first author). The 50 highest ranking on average are presented 
here, indicating marked variation between different studies for the miRNAs beyond the top-
10.  
 
Figure 4. Choice of samples. A) Workflow for the preparation of PPP from PRP. Addition of 
prostacyclin inhibits platelet activation during centrifugation. B) Concerns with regards to 
miRNA measurements in the different samples range from a contamination with leukocytes 
in PRP, proteolytic activity in serum to residual platelets in plasma. PRP and serum should 
reflect platelet miRNA content; PPP platelet miRNA release; plasma samples will reflect 
extracellular miRNA content but may additionally reflect either, platelet miRNA content or 
release. This depends on the amount of residual platelets in the plasma samples or platelet 
activation during plasma preparation, in particular during centrifugation. 
 
Figure 5. Discrepancy between miRNA quantitation by RT-qPCR and RNA 
sequencing. Average expression of 92 miRNAs was assessed in platelet-poor plasma from 
healthy subjects (n=12), using custom-made Exiqon LNA qPCR plates. Cycle-to-threshold 
(Ct) values are shown as 40-Ct (x-axis). Small RNA sequencing was performed with platelet-
poor plasma from healthy subjects (n=2). miR-486-5p is highlighted, showing high 
sequencing reads (y-axis) despite inferred mid-range abundance by qPCR. 
 
Figure 6. MiRNAs and platelet reactivity. Association of miR-126 and miR-223 levels in 
PPP to the Verify Now P2Y12 aggregation test (A) and the VASP phosphorylation assay (B) 
in patients on dual anti-platelet therapy for 30 days post acute coronary syndrome. Note that 
fewer samples were measured with the Verify Now (n=39) compared to the VASP assay 
(n=123). PRU, denotes P2Y12 Reaction Units (x-axis). Higher PRU values reflect higher 
P2Y12-mediated platelet reactivity. 
 
